162 related articles for article (PubMed ID: 19487444)
21. Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates.
Jones RN; Fritsche TR; Sader HS
Antimicrob Agents Chemother; 2008 Oct; 52(10):3763-75. PubMed ID: 18573936
[TBL] [Abstract][Full Text] [Related]
22. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.
Karlowsky JA; Adam HJ; Poutanen SM; Hoban DJ; Zhanel GG;
Diagn Microbiol Infect Dis; 2011 Mar; 69(3):342-7. PubMed ID: 21353963
[TBL] [Abstract][Full Text] [Related]
23. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN
Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
[TBL] [Abstract][Full Text] [Related]
24. Complestatin exerts antibacterial activity by the inhibition of fatty acid synthesis.
Kwon YJ; Kim HJ; Kim WG
Biol Pharm Bull; 2015; 38(5):715-21. PubMed ID: 25947917
[TBL] [Abstract][Full Text] [Related]
25. Rational design of broad spectrum antibacterial activity based on a clinically relevant enoyl-acyl carrier protein (ACP) reductase inhibitor.
Schiebel J; Chang A; Shah S; Lu Y; Liu L; Pan P; Hirschbeck MW; Tareilus M; Eltschkner S; Yu W; Cummings JE; Knudson SE; Bommineni GR; Walker SG; Slayden RA; Sotriffer CA; Tonge PJ; Kisker C
J Biol Chem; 2014 Jun; 289(23):15987-6005. PubMed ID: 24739388
[TBL] [Abstract][Full Text] [Related]
26. Fungal naphtho-γ-pyrones: Potent antibiotics for drug-resistant microbial pathogens.
He Y; Tian J; Chen X; Sun W; Zhu H; Li Q; Lei L; Yao G; Xue Y; Wang J; Li H; Zhang Y
Sci Rep; 2016 Apr; 6():24291. PubMed ID: 27063778
[TBL] [Abstract][Full Text] [Related]
27. Discovery of a potent enoyl-acyl carrier protein reductase (FabI) inhibitor suitable for antistaphylococcal agent.
Kim YG; Seo JH; Kwak JH; Shin KJ
Bioorg Med Chem Lett; 2015 Oct; 25(20):4481-6. PubMed ID: 26343826
[TBL] [Abstract][Full Text] [Related]
28. Enoyl-Acyl Carrier Protein Reductase I (FabI) Is Essential for the Intracellular Growth of Listeria monocytogenes.
Yao J; Ericson ME; Frank MW; Rock CO
Infect Immun; 2016 Dec; 84(12):3597-3607. PubMed ID: 27736774
[TBL] [Abstract][Full Text] [Related]
29. Implementation of permeation rules leads to a FabI inhibitor with activity against Gram-negative pathogens.
Parker EN; Drown BS; Geddes EJ; Lee HY; Ismail N; Lau GW; Hergenrother PJ
Nat Microbiol; 2020 Jan; 5(1):67-75. PubMed ID: 31740764
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial activity of everninomicin against clinical isolates of Enterococcus spp., Staphylococcus spp., and Streptococcus spp. tested by Etest.
Terakubo S; Takemura H; Yamamoto H; Ikejima H; Kunishima H; Kanemitsu K; Kaku M; Shimada J
J Infect Chemother; 2001 Dec; 7(4):263-6. PubMed ID: 11810596
[TBL] [Abstract][Full Text] [Related]
31. In vitro activity and beta-lactamase stability of the new oral cephalosporin Bay v 3522.
Chin NX; Gu JW; Neu HC
Eur J Clin Microbiol Infect Dis; 1990 Sep; 9(9):685-91. PubMed ID: 2226499
[TBL] [Abstract][Full Text] [Related]
32. Verrulactone C with an unprecedented dispiro skeleton, a new inhibitor of Staphylococcus aureus enoyl-ACP reductase, from Penicillium verruculosum F375.
Kim N; Sohn MJ; Koshino H; Kim EH; Kim WG
Bioorg Med Chem Lett; 2014 Jan; 24(1):83-6. PubMed ID: 24332629
[TBL] [Abstract][Full Text] [Related]
33. Activation of Exogenous Fatty Acids to Acyl-Acyl Carrier Protein Cannot Bypass FabI Inhibition in Neisseria.
Yao J; Bruhn DF; Frank MW; Lee RE; Rock CO
J Biol Chem; 2016 Jan; 291(1):171-81. PubMed ID: 26567338
[TBL] [Abstract][Full Text] [Related]
34. Panosialins, inhibitors of enoyl-ACP reductase from Streptomyces sp. AN1761.
Kwon YJ; Sohn MJ; Oh T; Cho SN; Kim CJ; Kim WG
J Microbiol Biotechnol; 2013 Feb; 23(2):184-8. PubMed ID: 23412060
[TBL] [Abstract][Full Text] [Related]
35. Meleagrin, a new FabI inhibitor from Penicillium chryosogenum with at least one additional mode of action.
Zheng CJ; Sohn MJ; Lee S; Kim WG
PLoS One; 2013; 8(11):e78922. PubMed ID: 24312171
[TBL] [Abstract][Full Text] [Related]
36. Studies of Staphylococcus aureus FabI inhibitors: fragment-based approach based on holographic structure-activity relationship analyses.
Kronenberger T; Asse LR; Wrenger C; Trossini GH; Honorio KM; Maltarollo VG
Future Med Chem; 2017 Feb; 9(2):135-151. PubMed ID: 28128024
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of gallium maltolate against Staphylococci in logarithmic, stationary, and biofilm growth phases: comparison of conventional and calorimetric susceptibility testing methods.
Baldoni D; Steinhuber A; Zimmerli W; Trampuz A
Antimicrob Agents Chemother; 2010 Jan; 54(1):157-63. PubMed ID: 19805560
[TBL] [Abstract][Full Text] [Related]
38. In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant Staphylococci and Streptococci.
Sader HS; Johnson DM; Jones RN
Antimicrob Agents Chemother; 2004 Jan; 48(1):53-62. PubMed ID: 14693518
[TBL] [Abstract][Full Text] [Related]
39. Comparative in vitro activity of linezolid and five other antimicrobials against nosocomial isolates of methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis and vancomycin-resistant Enterococcus faecium.
Metallidis S; Chatzidimitriou M; Nikolaidis P; Tsona A; Bisiklis A; Kollaras P; Tsiakiri E; Koumentaki E; Alexiou-Daniel S
J Chemother; 2003 Oct; 15(5):442-8. PubMed ID: 14603881
[TBL] [Abstract][Full Text] [Related]
40. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
